Skip to main content

Advertisement

SpringerLink
Log in

Angiotensin vaccination: What is the prospect of success?

  • Published:
Current Hypertension Reports Aims and scope Submit manuscript

Abstract

Over many decades, several attempts have been made to treat hypertension using a vaccination strategy to inhibit the renin-angiotensin system. Renin vaccination successfully inhibited renin activity and reduced blood pressure in animal models, but caused autoimmune disease of the kidney. By contrast, most previous studies of angiotensin vaccination failed to reduce blood pressure in animal models, despite producing high titers of antibodies that prevented the pressor response to exogenous angiotensins. Angiotensin vaccination is being revisited as a strategy for treating hypertension, in the hope that new conjugates of angiotensin I and angiotensin II will produce antibodies of sufficient titer and affinity to reduce blood pressure in patients with hypertension. A recent clinical study of angiotensin II vaccination provided some cause for optimism, but many hurdles remain before this strategy can compete with current oral medications for hypertension.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Elliott WJ: The economic impact of hypertension. J Clin Hypertens (Greenwich) 2003, 5:3–13.

    Article  Google Scholar 

  2. Burnier M: Long-term compliance with antihypertensive therapy: another facet of chronotherapeutics in hypertension. Blood Press Monit 2000, 5(Suppl 1):S31–S34.

    Article  PubMed  Google Scholar 

  3. Blood Pressure Lowering Treatment Trialists’ Collaboration: Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectivelydesigned overviews of randomised trials. Lancet 2003, 362:1527–1535.

    Article  CAS  Google Scholar 

  4. The SOLVD Investigators: Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991, 325:293–302.

    Google Scholar 

  5. The SOLVD Investigators: Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992, 327:685–691.

    Google Scholar 

  6. The Heart Outcomes Prevention Evaluation Study Investigators: Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000, 342:145–153.

    Article  Google Scholar 

  7. Pitt B, Poole-Wilson PA, Segal R, et al.: Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial-the Losartan Heart Failure Survival Study ELITE II. Lancet 2000, 355:1582–1587.

    Article  PubMed  CAS  Google Scholar 

  8. Brenner BM, Cooper ME, de Zeeuw D, et al.: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001, 345:861–869.

    Article  PubMed  CAS  Google Scholar 

  9. Dahlof B, Devereux RB, Kjeldsen SE, et al.: Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002, 359:995–1003.

    Article  PubMed  CAS  Google Scholar 

  10. PROGRESS Collaborative Group: Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet 2001, 358:1033–1041.

    Article  Google Scholar 

  11. Michel J-B, Guettier C, Reade R, et al.: Immunologic approaches to blockade of the renin-angiotensin system: A review. AmHeart J 1989, 117:756–767.

    CAS  Google Scholar 

  12. Michel JB, Galen FX, Guettier C, et al.: Immunological approach to blockade of the renin-substrate reaction. J Hypertens Suppl 1989, 7:S63–S70.

    PubMed  CAS  Google Scholar 

  13. Michel JB: Renin-angiotensin vaccine: old story, new project ‘efficacy versus safety’. Clin Sci (Lond) 2004, 107:145–147.

    CAS  Google Scholar 

  14. Menard J: A vaccine for hypertension. J Hypertens 2007, 25:41–46.

    PubMed  CAS  Google Scholar 

  15. Campbell DJ, Duncan A-M, Kladis A, Harrap SB: Angiotensin peptides in spontaneously hypertensive and normotensive Donryu rats. Hypertension 1995, 25:928–934.

    PubMed  CAS  Google Scholar 

  16. Downham MR, Auton TR, Rosul A, et al.: Evaluation of two carrier protein-angiotensin I conjugate vaccines to assess their future potential to control high blood pressure (hypertension) in man. Br J Clin Pharmacol 2003, 56:505–512.

    Article  PubMed  CAS  Google Scholar 

  17. Brown MJ, Coltart J, Gunewardena K, et al.: Randomized double-blind placebo-controlled study of an angiotensin immunotherapeutic vaccine (PMD3117) in hypertensive subjects. Clin Sci (Lond) 2004, 107:167–173.

    CAS  Google Scholar 

  18. Ambühl PM, Tissot AC, Fulurija A, et al.: A vaccine for hypertension based on virus-like particles: preclinical efficacy and phase I safety and immunogenicity. J Hypertens 2007, 25:63–72.

    PubMed  Google Scholar 

  19. Tissot AC, Maurer P, Nussberger J, et al.: Effect of immunisation against angiotensin II with CYT006-AngQb on ambulatory blood pressure: a double-blind, randomised, placebo-controlled phase IIa study. Lancet 2008, 371:821–827.

    Article  PubMed  CAS  Google Scholar 

  20. Campbell DJ: The site of angiotensin production. J Hypertens 1985, 3:199–207.

    Article  PubMed  CAS  Google Scholar 

  21. Wiig H, Gyenge CC, Tenstad O: The interstitial distribution of macromolecules in rat tumours is influenced by the negatively charged matrix components. J Physiol 2005, 567:557–567.

    Article  PubMed  CAS  Google Scholar 

  22. Admiraal PJJ, Derkx FHM, Danser AHJ, et al.: Metabolism and production of angiotensin I in different vascular beds in subjects with hypertension. Hypertension 1990, 15:44–55.

    PubMed  CAS  Google Scholar 

  23. Maillard MP, Wurzner G, Nussberger J, et al.: Comparative angiotensin II receptor blockade in healthy volunteers: the importance of dosing. Clin Pharmacol Ther 2002, 71:68–76.

    Article  PubMed  CAS  Google Scholar 

  24. Nussberger J, Wuerzner G, Jensen C, Brunner HR: Angiotensin II suppression in humans by the orally active renin inhibitor Aliskiren (SPP100): comparison with enalapril. Hypertension 2002, 39:e1–e8.

    Article  PubMed  CAS  Google Scholar 

  25. Admiraal PJJ, Derkx FHM, Danser AHJ, et al.: Intrarenal de novo production of angiotensin I in subjects with renal artery stenosis. Hypertension 1990, 16:555–563.

    PubMed  CAS  Google Scholar 

  26. Refetoff S: Inherited thyroxine-binding globulin abnormalities in man. Endocr Rev 1989, 10:275–293.

    Article  PubMed  CAS  Google Scholar 

  27. Stockigt J: Assessment of thyroid function: towards an integrated laboratory-clinical approach. Clin Biochem 2003, 24:109–122.

    Google Scholar 

  28. Lacourciere Y, Asmar R: A comparison of the efficacy and duration of action of candesartan cilexetil and losartan as assessed by clinic and ambulatory blood pressure after a missed dose, in truly hypertensive patients: a placebo-controlled, forced titration study. Candesartan/Losartan study investigators. Am J Hypertens 1999, 12:1181–1187.

    Article  PubMed  CAS  Google Scholar 

  29. Coca A, Calvo C, Garcia-Puig J, et al.: A multicenter, randomized, double-blind comparison of the efficacy and safety of irbesartan and enalapril in adults with mild to moderate essential hypertension, as assessed by ambulatory blood pressure monitoring: the MAPAVEL Study (Monitorizacion Ambulatoria Presion Arterial APROVEL). Clin Ther 2002, 24:126–138.

    Article  PubMed  CAS  Google Scholar 

  30. Prichard BN, Jager BA, Luszick JH, et al.: Placebo-controlled comparison of the efficacy and tolerability of once-daily moxonidine and enalapril in mild to moderate essential hypertension. Blood Press 2002, 11:166–172.

    Article  PubMed  CAS  Google Scholar 

  31. Ready T: Blood pressure vaccine shot down by safety concerns. Nat Med 2005, 11:1262.

    Article  PubMed  CAS  Google Scholar 

  32. Bachmann MF, Nussberger J, Tissot AC, Jennings GT: Reply to ‘Blood pressure vaccine shot down by safety concerns.’ Nat Med 2006, 12:270.

    Article  PubMed  CAS  Google Scholar 

  33. Samuelsson O, Herlitz H: Vaccination against high blood pressure: a new strategy. Lancet 2008, 371:788–789.

    Article  PubMed  Google Scholar 

  34. Shechter Y, Maron R, Elias D, Cohen IR: Autoantibodies to insulin receptor spontaneously develop as anti-idiotypes in mice immunized with insulin. Science 1982, 216:542–545.

    Article  PubMed  CAS  Google Scholar 

  35. Batarseh H, Thompson RA, Odugbesan O, Barnett AH: Insulin receptor antibodies in diabetes mellitus. Clinical and experimental immunology 1988, 71:85–90.

    PubMed  CAS  Google Scholar 

  36. Couraud PO: Anti-angiotensin II anti-idiotypic antibodies bind to angiotensin II receptor. J Immunol 1987, 138:1164–1168.

    PubMed  CAS  Google Scholar 

  37. Xia Y, Ramin SM, Kellems RE: Potential roles of angiotensin receptor-activating autoantibody in the pathophysiology of preeclampsia. Hypertension 2007, 50:269–275.

    Article  PubMed  CAS  Google Scholar 

  38. Dragun D, Muller DN, Brasen JH, et al.: Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection. N Engl J Med 2005, 352:558–569.

    Article  PubMed  CAS  Google Scholar 

  39. Mooser V, Nussberger J, Juillerat L, et al.: Reactive hyperreninemia is a major determinant of plasma angiotensin II during ACE inhibition. J Cardiovasc Pharmacol 1990, 15:276–282.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. St. Vincent’s Institute of Medical Research, 41 Victoria Parade, Fitzroy, Victoria, 3065, Australia

    Duncan J. Campbell

Authors
  1. Duncan J. Campbell
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Duncan J. Campbell.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Campbell, D.J. Angiotensin vaccination: What is the prospect of success?. Current Science Inc 11, 63–68 (2009). https://doi.org/10.1007/s11906-009-0012-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11906-009-0012-y

Keywords

Search

Navigation